ARTICLE | Clinical News
TT-401: Phase II data
February 8, 2016 8:00 AM UTC
Top-line data from a double-blind, international Phase II trial in 420 Type II diabetics showed that once-weekly 10, 15, 30 and 50 mg subcutaneous LY2944876 all met the primary endpoint of reducing Hb...